Publications

Selected Publications (2005-2021), from a total of > 400 publications (H-index > 50)

293. Bicher M, Rippinger C, Urach C, Brunmeir D, Siebert I, Popper N. Evaluation of Contact-Tracing Policies against the Spread of SARS-CoV-2 in Austria: An Agent-Based Simulation. Medical Decision Making 2021, [in press].
292. Ammenwerth E, Neyer S, Hörbst A, Mueller G, Siebert U, Schnell-Inderst P. Adult patient access to electronic health records. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD012707. DOI: 10.1002/14651858.CD012707.pub2. PMID: 33634854.
291. Schnell-Inderst P, Steigenberger C, Mertz M, Otto I, Flatscher-Thöni M, Siebert, U Therapie mit Mistelextrakten bei Patientinnen mit Mammakarzinom als Ergänzung zur konventionellen Krebstherapie im Vergleich zur konventionellen Krebstherapie allein. Medizinische Wirksamkeit und Sicherheit, Kosten und Kosteneffektivität, Patientenaspekte, soziale Aspekte und ethische Bewertung. GMS Health Innovations and Technologies (HInT) 2021 [in press].
290. Fiedler L, Hallsson L, Tscharre M, Oebel S, Pfeffer M, Schönbauer R, Tokarska L, Stix L, Haiden A, Kraus J, Blessberger H, Siebert U, Roithinger FX. Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis. J Clin Med 2021,10:807. Doi: doi.org/10.3390/jcm10040807. PMID: 33671264; PMCID: PMC7922984.
289. Siebert U, Milev S, Zou D, Litkiewicz M, Gaggin HK, Tirapelle L, Masson S, Januzzi JL. Economic Evaluation of an N-terminal pro B-type Natriuretic Peptide-supported Diagnostic Strategy among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. Am J Cardiol. 2021 Feb 20:S0002-9149(21)00145-4. doi: 10.1016/j.amjcard.2021.01.036. Epub ahead of print. PMID: 33617809. [in press].
288. Rippinger C, Bicher M, Urach C, Brunmeir D, Weibrecht N, Zauner G, Sroczynski G, Jahn B, Mühlberger N, Siebert U, Popper N. Evaluation of undetected cases during the COVID-19 epidemic in Austria. BMC Infectious Diseases 2021;21(1):70. doi: 10.1186/s12879-020-05737-6. PMID: 33441091; PMCID: PMC7805565.
287. Schaffner M, Rochau U, Mühlberger N, Conrads-Frank A, Qerimi Rushaj V, Sroczynski G, Koukkou E, Thuesen BH, Völzke H, Oberaigner W, Siebert U. The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany. Endocr Connect. 2021;10(1):1-12. doi: 10.1530/EC-20-0384. PMID: 33263563; PMCID: PMC7849460.
286. Leitinger M, Poppert KN, Mauritz M, Rossini F, Zimmermann G, Rohracher A, Kalss G, Kuchukhidze G, Höfler J, Bosque Varela P, Kreidenhuber R, Volna K, Neuray C, Kobulashvili T, Granbichler CA, Siebert U, Trinka E. Status epilepticus admissions during the COVID-19 pandemic in Salzburg-A population-based study. Epilepsia 2020 Dec;61(12):e198-e203. doi: 10.1111/epi.16737. PMID: 33140437; PMCID: PMC7756208.
285. Schaffner M, Rochau U, Stojkov I, Qerimi Rushaj V, Völzke H, Marckmann G, Lazarus JH, Oberaigner W, Siebert U. Barriers Against Prevention Programs for Iodine Deficiency Disorders in Europe: A Delphi Study. Thyroid 2020. doi: 10.1089/thy.2020.0065. Epub ahead of print. PMID: 32912084.
284. Schaffner M, Mühlberger N, Conrads-Frank A, Qerimi Rushaj V, Sroczynski G, Koukkou E, Thuesen BH, Völzke H, Oberaigner W, Siebert U, Rochau U. Benefits and Harms of a Prevention Program for Iodine Deficiency Disorders: Predictions of the Decision-Analytic EUthyroid Model. Thyroid 2021;31(3): 494-508. doi: 10.1089/thy.2020.0062. Epub 2020 Oct 21. PMID: 32847437.
283. Klompmaker S, de Rooij T, Koerkamp BG, Shankar A, Siebert U, Besselink MG, Moser AJ, in collaboration with the Dutch Pancreatic Cancer Group. International validation of reduced major morbidity after minimally invasive distal pancreatectomy compared with open pancreatectomy. Ann Surg 2019 Ann Surg 2019 Oct 17. doi: 10.1097/SLA.0000000000003659. Online ahead of print. [in press].
282. Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M, Felson DT, McCloskey EV, Watzl B, Hofbauer LC, Felsenberg D, Willett WC, Dawson-Hughes B, Manson JE, Siebert U, Theiler R, Staehelin HB, de Godoi Rezende Costa Molino C, Chocano-Bedoya PO, Abderhalden LA, Egli A, Kanis JA, Orav EJ, Group D-HR. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. JAMA 2020;324(18):1855-1868. PMID: 33170239
281. Rochau U, Stojkov I, Conrads-Frank A, Borba HH, Koinig KA, Arvandi M, Marrewijk van C, Garelius H, Germing U, Symeonidis A, Sanz GF, Fenaux P, de Witte T, Efficace F, Siebert U, Stauder R. Development of a Core Outcome Set for Myelodysplastic Syndromes – A Delphi Study from the EUMDS Registry Group. Br J Haematol 2020 191(3):405-417. doi: 10.1111/bjh.16654. Epub 2020 May 14. PMID: 32410281.
280. Pellecchia MT, Stankovic I, Fanciulli A, Krismer F, Meissner WG, Palma JA, Panicker JN, Seppi K, Wenning GK, Movement Disorder Society Multiple System Atrophy Study Group. Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. Mov Disord Clin Pract. 2020 Sep 3;7(7):750-762. doi: 10.1002/mdc3.13052. PMID: 33043073; PMCID: PMC7533961.
279. Walter E, Hausberger SC, Groß E, Siebert U. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria, Journal of Medical Economics 2020;23(10):1061-1071. doi: 10.1080/13696998.2020.1801187. Epub 2020 Aug 8. PMID: 32713223.
278. Latimer NR, White IR, Tilling K, Siebert U. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding. Stat Methods Med Res 2020;29(10):2900-2918. doi: 10.1177/0962280220912524. Epub 2020 Mar 30. PMID: 32223524; PMCID: PMC7436445.
277. Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, Platt RW, Siebert U, Socías ME, Tsui JI, Wood E, Nosyk B. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. BMJ Open. 2020 Sep 9;10(9):e036102. doi: 10.1136/bmjopen-2019-036102. PMID: 32912944; PMCID: PMC7482450.
276. Morawetz D, Blank C, Koller A, Arvandi M, Siebert U, Schobersberger W. Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis. J Strength Cond Res. 2020;34(9):2697-2702. doi: 10.1519/JSC.0000000000002867. PMID: 30908366
275. Sroczynski G, Esteban E, Widschwendter A, Oberaigner W, Borena W, von Laer D, Hackl M, Endel G, Siebert U. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria. Int J Cancer 2020;147(4):1131-1142.
274. Sroczynski G, Esteban E, Widschwendter A, Oberaigner W, Borena W, von Laer D, Hackl M, Endel G, Siebert U. Reducing overtreatment associated with overdiagnosis in cervical cancer screening – A model-based benefit-harm analysis for Austria. International Journal of Cancer 2020;147(4):1131-1142. doi: 10.1002/ijc.32849. Epub 2020 Jan 13. PMID: 31872420.
273. Schullian P, Gertl A, Laimer G, Putzer D, Siebert U, Levy E, Bale R. Quality of life analysis after stereotactic radiofrequency ablation of liver tumors. Sci Rep. 2020 Jul 30;10(1):12809. doi: 10.1038/s41598-020-69331-1. PMID: 32732877; PMCID: PMC7393379.
272. Sroczynski G, Gogollari A, Conrads-Frank A, Hallsson LR, Pashayan N, Widschwendter M, Siebert U. Cost-effectiveness of early detection and prevention strategies for endometrial cancer-A systematic review. Cancers (Basel). 2020;12(7):1874. doi: 10.3390/cancers12071874.
271. Briggs A, Daniele B, Dick K, Jeffry Evans TR, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020;122(12):1754-1759. doi:10.1038/s41416-020-0817-7. PMID: 32265508
270. Podgorica N, Flatscher-Thöni M, Deufert D, Siebert U, Ganner M. A systematic review of ethical and legal issues in elder care. Nursing Ethics 2020; 969733020921488. doi: 10.1177/0969733020921488. Online ahead of print.. PMID: 32468910
269. Hoffmann S, Crispin A, Lindoerfer D, Sroczynski G, Siebert U, Mansmann U, and FARKOR Consortium. Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR. BMC Gastroenterol 2020; 20(1):131. doi: 10.1186/s12876-020-01247-6. PMID: 32370777; PMCID: PMC7201550.
268. Bose-O’Reilly S, Lettmeier B, Shoko D, Roider G, Drasch G, Siebert U. Infants and mothers levels of mercury in breast milk, urine and hair, data from an artisanal and small-scale gold mining area in Kadoma / Zimbabwe. Environ Res 2020;184:109266. doi: 10.1016/j.envres.2020.109266. Epub 2020 Feb 20. PMID: 32126374.
267. Faulkner E, Holtorf AP, Walton S, Liu CY, Lin H, Biltaj E, Brixner D, Barr C, Oberg J, Shandhu G, Siebert U, Snyder SR, Tiwana S, Watkins J, IJzerman MJ, Payne K.. Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value Health. 2020;23(5):529-539. doi: 10.1016/j.jval.2019.11.010. Epub 2020 Apr 1. Erratum in: Value Health. 2020 Nov;23(11):1522. PMID: 32389217.
266. Rochau U. Qerimi Rushaj V, Schaffner M, Schönhensch M, Stojkov I, Jahn B, Hubalewska-Dydejczyk A, Erlund I, H Thuesen B, Zimmermann M, Moreno-Reyes R, Lazarus JH, Völzke H, Siebert U. Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview. Thyroid 2020;30(5):746-758. doi: 10.1089/thy.2018.0776. Epub 2020 Feb 26. PMID: 31964247.
265. Sroczynski G, Gogollari S, Kuehne F, Hallsson L, Widschwendter M, Pashayan N, Siebert U. A systematic review on cost-effectivenes studies evaluating ovarian cancer early detection and prevention strategies. Cancer Prevention Research 2020 Cancer Prev Res (Phila). 2020;13(5):429-442. doi:10.1158/1940-6207.CAPR-19-0506. PMID: 32071120
264. Stauder R, Lambert J, Desruol-Allardin S, Savre I, Gaugler L, Stojkov I, Siebert U, Chevrou-Séverac H. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: literature review and landscape analysis. European Journal of Haematology 2020; 104(5):476-487. PMID: 31985078
263. Vukićević Đ, Rochau U, Savić A, Schaffner M, Jevđević M, Stojkov I, Sroczynski G, Willenbacher W, Jahn B, Siebert U. Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia. Zdr Varst 2020;59(2):83-91. doi: 10.2478/sjph-2020-0011. PMID: 32952707
262. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, Wagner G, Siebert U, Christof C, Zachariah C, Gartlehner G. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev 2020;4(4): Art.No.: CD013574. doi: 10.1002/14651858.CD013574.
261. Gothe H, Matteucci Gothe R, Arvandi M, Hintringer K, Toell T, Oberaigner W, Rajsic S, Kugler J, Kiechl S, Willeit J, Siebert U. [Linkage of Clinical and Claims Data in the Evaluation of Post-Stroke Care – SeDaStro: Experiences from the Tyrolian StrokeCard Program]. [German]. Gesundheitswesen 2020; 82(S 02): S122-S130.
260. Lechner C, Schnaiter D, Siebert U, Böse-O’Reilly S. Effects of Motorcycle Noise on Annoyance-A Cross-Sectional Study in the Alps. Int J Environ Res Public Health 2020; 17(5):1580. doi: 10.3390/ijerph17051580.
259. Leitinger M, Trinka E, Zimmermann G, Granbichler CA, Kobulashvili T, Siebert U. Epidemiology of status epilepticus in adults: Apples, pears, and oranges — A critical review. Epilepsy & Behavior 2020;103 (Pt A): 106720. doi: 10.1016/j.yebeh.2019.106720.
258. Schomaker M, Kühne F, Siebert U. Re: “Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples with Apples”. [Letter]. Am J Epidemiol. 2020;189(1)77-78. pii: kwz194. doi: 10.1093/aje/kwz194.
257. Jahn B, Sroczynski G, Bundo M, Muhlberger N, Puntscher S, Todorovic J, Rochau U, Oberaigner W, Koffijberg H, Fischer T, Schiller-Fruehwirth I, Ofner D, Renner F, Jonas M, Hackl M, Ferlitsch M, Siebert U, Austrian Colorectal Cancer Screening Model Group. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. BMC Gastroenterol 2019;19(1):209.doi: 10.1186/s12876-019-1121-y.
256. Borba HHL, Rochau U, Wiens A, Sroczynski G, Siebert U, Ferreira VL, Minowa E, Pontarolo R. Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective. Value Health Reg Issues 2019;20:95-102.
255. Stella SF, Polanczyk CA, Arvandi M, Siebert U. Cost utility of fractional flow reserve guided percutaneous coronary intervention in multivessel coronary artery disease in Brazil. International Journal for Quality in Health Care. 2019; 31(9):676-681. doi: 10.1093/intqhc/mzy240.
254. Spizzo G, Siebert U, Gastl G, Voss A, Schuster K, Leonard R, Seeber A. Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. Cost Eff Resour Alloc 2019; 17:23. doi: 10.1186/s12962-019-0191-6. PMID: 31641338; PMCID: PMC6802110.
253. Sommer I, Titscher V, Teufer B, Klerings I, Nußbaumer-Streit B, Szelag M, Affengruber L, Wagner G, Glechner A, Kien C, Ebenberger A, Schiller-Frühwirth I, Dorner TE, Siebenhofer A, Haditsch B, Bachler H, Siebert U, Gartlehner G. [Evidence-based recommendations for the revision of the Austrian periodic health examination]. [German]. Wien Med Wochenschr. 2019;169(13-14):339-349.
252. Gothe H, Rajsic S, Vukicevic D, Schönfelder T, Jahn B, Seiger-Gritsch S, Brixner D, Popper N, Gottfried E, Siebert U. Algorithms to Identify COPD in Health Systems with and without Access to ICD Coding: A Systematic Review. BMC Health Services Research 2019;19(1):737. doi.org/10.1186/s12913-019-4574-3.
251. Kuehne F, Jahn B, Conrads-Frank A, Bundo M, Arvandi M, Endel F, Popper N, Endel G, Urach C, Gyimesi M, Murray E, Danaei G, GazianoTA, Pandya A, Siebert U. Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. J Comp Eff Res 2019;8(12):1013-25.
250. Latimer NR, White IR, Abrams KR, Siebert U. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? Statistical Methods in Medical Research 2019;28(8):2475-93. doi: 10.1177/0962280218780856.
249. Ammenwerth E, Hoerbst A, Lannig S, Mueller G, Siebert U, Schnell-Inderst P. Effects of Adult Patient Portals on Patient Empowerment and Health-Related Outcomes: A Systematic Review. Stud Health Technol Inform 2019;264:1106-10.
248. Miksch F, Jahn B, Espinosa KJ, Chhatwal J, Siebert U, Popper N. Why should we apply ABM for decision analysis for infectious diseases?-An example for dengue interventions. PLosOne 2019;14(8):e0221564.
247. Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Endel G, Wilbacher I, Malbaski N, Popper N, Chhatwal J, Greenberg D, Mauskopf J, Siebert U. Budget Impact Analysis of Cancer Screening: A Methodological Review. Appl Health Econ Health Policy. 2019;17(4):493-511.
246. Jahn B, Kurzthaler C, Chhatwal J, Elbasha EE, Conrads- Frank A, Rochau U, Sroczynski G, Urach C, Bundo M, Popper N, Siebert U. Alternative conversion methods for transition probabilities in state-transition models – validity and impact on comparative effectiveness and cost effectiveness. Med Decis Making 2019;39(5):509-22.
245. Vukicevic D, Rochau U, Savic A, Buchberger M, Sroczynski G, Siebert U. Costs of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care system. Medicinski Pregled / Medical Review 2019;72(3-4):88-97. DOI: 10.2298/MPNS1904088V.
244. Latimer N, Abrams KR, Siebert U. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Medical Research Methodology 2019;19(1):69. doi: 10.1186/s12874-019-0709–9.
243. Adarkwah CC, Jegan N, Heinzel-Gutenbrunner M, Kühne F, Siebert U, Popert U, Donner-Banzhoff N, Kürwitz S. The Optimizing-Risk-Communication (OptRisk) randomized trial – impact of decision-aid-based consultation on adherence and perception of cardiovascular risk. Patient Preference and Adherence 2019:13 441–52.
242. Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 2 on Triage, Treatment and Follow-up. Geburtshilfe Frauenheilkd. (eJournal) 2019;79(2):160-176. doi: 10.1055/a-0828-7722. Epub 2019 Feb 18.
241. Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia. Geburtshilfe Frauenheilkd. (eJournal) 2019;79(2):148-159. doi: 10.1055/a-0818-5440. Epub 2019 Feb 18.
240. Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, Siebert U. Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ. 2019;20(1):107-134. doi: 10.1007/s10198-018-0984-0.
239. Kristensen FB, Husereau D, Augustovski F, Berger ML, Bond K, Booth A, Bridges JFP, Drummond M, Grimshaw J, Hui M, Ijzerman MJ, Jonsson E, Ollendorf DA, Rüther A, Siebert U, Sharma J, Wailoo A. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health 2019;22(1):13-20.
238. Leitinger M, Trinka E, Giovannini G, Zimmermann G, Florea G, Rohracher A, Kalss G, Neuray C, Kreidenhuber R, Höfler J, Kuchukhidze G, Granbichler C, Dobesberger J, Novak HF, Pilz G, Meletti S, Siebert U. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcome. Epilepsia 2019;60(1):53-62.
237. Veličković VM, Rochau U, Conrads-Frank A, Kee F, Blankenberg S, Siebert U. Systematic assessment of decision-analytic models evaluating diagnostic tests for acute myocardial infarction based on cardiac troponin assays. Expert Review of Pharmacoeconomics & Outcomes Research 2018;18(6):619-640. doi: 10.1080/14737167.2018.1512857.
236. Richter AK, Klimek L, Merk HF, Mülleneisen N, Renz H, Wehrmann W, Werfel T, Hamelmann E, Siebert U, Sroczynski G, Wasem J, Biermann-Stallwitz J. Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. Eur J Health Econ. 2018; 19(9):1229-1242. doi: 10.1007/s10198-018-0970-6.
235. Siebert U; Hallsson LR. To stop or not to stop: a value of information view. [Commentary]. European Journal of Epidemiology 2018;13(9):785-787.
234. Veličković VM, Borisenko O, Svensson M, Spelman T, Siebert U. Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. PLoS ONE 2018;13(9): e0204643. https://doi.org/10.1371/journal.pone.0204643.
233. Völzke H; Erlund I; Hubalewska-Dydejczyk A; Ittermann T; Peeters RP; Rayman M; Buchberger M; Siebert U; Thuesen BH; Zimmermann MB; Grunert S; Lazarus JH. How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond? European Thyroid Journal. 2018;7(4):193-200.
232. Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse A-M, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N, FORECEE (4C) Consortium. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology 2018;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Review.
231. Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E. Health state utilities among contemporary prostate cancer patients on active surveillance. Transl Androl Urol. 2018;7(2):197-202. doi: 10.21037/tau.2017.03.80.
230. Arvandi M, Strasser B, Volaklis K, Ladwig KH, Grill E, Gothe RM, Horsch A, Laxy M, Siebert U, Peters A, Thorand B, Meisinger C. Mediator effect of balance problems on association between grip strength and falls in older adults: Results from the KORA-Age Study. Gerontology and Geriatric Medicine 2018;4:2333721418760122. doi: 10.1177/2333721418760122. eCollection 2018 Jan-Dec. [in press].
229. Schnell-Inderst P, Hunger T, Conrads-Frank A, Arvandi M, Siebert U. Ten recommendations for assessing the comparative effectiveness of therapeutic medical devices: A targeted review and adaptation. J Clin Epidemiol. 2018;94:97-113
228. Seidl A, Danner M, Wagner CJ, Sandmann FG, Sroczynski G, Stürzlinger H, ZsifkovitsJ, Schwalm A, Lhachimi SK, Siebert U, Gerber-Grote A. Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. MDM Policy & Practice 2018;3(1);1-11. doi: 10.1177/2381468317751923.
227. Schnell-Inderst P, Hunger T, Conrads-Frank A, Arvandi M, Siebert U. Recommendations for primary studies evaluating therapeutic medical devices were identified and systematically reported through reviewing existing guidance. J Clin Epidemiol. 2018;94:46-58.
226. Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, Siebert U, Cook-Deegan R, Green RC. A randomized controlled trial of disclosing genetic risk information for Alzheimer’s disease via telephone. Genetics in Medicine 2018:20(1):132-141.
225. Perleth M, Schnell-Inderst P, Rüther A., Raatz H, Kolominsky-Rabas P, Panteli D, Siebert U, Berndt N, Wahlster P. Das Curriculum Health Technology Assessment (HTA), Version 2.0, GMS Health Technology Assessment 2017;13:Doc03:1-10.
224. Geiger-Gritsch S, Buchberger W, Knapp R, Daniaux M, Tabar L, Marth, Hubalek M, Edlinger M, Siebert U, Oberaigner W. Reduction in advanced breast cancer and changes in breast cancer therapy after introduction of a mammography screening program in Tyrol/Austria. The Breast 2017;33:178-182. doi: 10.1016/j.breast.2017.04.002.
223. Adarkwah CC, Jegan N, Kuerwitz S, Heinzel-Gutenbrunner M, Kuehne F, Siebert U, Popert U, Donner-Banzhoff N. [Cardiovascular risk assessment in younger patients: Implications of different risk representation on risk perception and decisional conflict]. Kardiovaskuläre Risikoberatung bei jüngeren Patienten. Einflüsse der Darstellungsform auf die subjektive Risikowahrnehmung und den Entscheidungskonflikt. Z Allg Med 2017;93(9):353-359
222. Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sorczynski G, Paulden M, Bundo M, Stenehjem D, Brixner D, Krahn M, Siebert U. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer 2017 Oct 16;17(1):685 [in press]. doi: 10.1186/s12885-017-3603-z.
221. Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.Eur Urol. 2017 Dec;72(6):899-907.
220. Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U. Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC. BMC Cancer 2017;6(7):563-574.
219. Schiller-Fruehwirth I, Jahn B, Einzinger P, Zauner G, Urach C, Siebert U. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria. Value Health. 2017;20(8):1048-1057.
218. Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, Siebert U, Marth C, Buchberger W. Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria. Breast. 2017;33:178-182.
217. Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U. Benefits and Harms of Prostate Cancer Screening – Predictions of the ONCOTYROL Prostate Cancer Outcome and Policy Model. BMC Public Health 2017;17(1):596, doi: 10.1186/s12889-017-4439-9. [Open Access: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4439-9]
216. Schiller-Frühwirth IC, Jahn B, Arvandi M, Siebert U. Cost-effectiveness models in breast cancer screening in the general population: A systematic review. Appl Health Econ Health Policy 2017;15(3):333-351. doi:10.1007/s40258-017-0312-3.
215. Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E. Health state utilities among contemporary prostate cancer patients on active surveillance. Transl Androl Urol 2017. doi: 10.21037/tau.2 [in press].
214. Czarnecka-Kujawa K, Rochau U, Siebert U, Atenafu E, Darling G, Waddell TK, De Perrot M, Pierre A, Cypel M, Keshavjee S, Yasufuku K. Cost-Effectiveness of Mediastinal Lymph Node Staging in NSCLC. The Journal of Thoracic and Cardiovascular Surgery 2017;153(6):1567-157.
213. Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? BMC Health Services Research 2017;17(1):289. doi: 10.1186/s12913-017-2205-4. [in press].
212. Bose-O’Reilly S, Bernaudat L, Siebert U, Roider G, Nowak D, Drasch G. Signs and symptoms of mercury exposed gold miners. International Journal of Occupational Medicine and Environmental Health 2017; 30(2):249-269.
211. Schnell-Inderst P, Iglesias CP, Arvandi M, Ciani O, Matteucci Gothe R, Peters J, Blom AW, Taylor RS, Sculpher M, Siebert U. Synthesis of RCT and observational data: A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. Health Economics 2017;26(Suppl. 1):46–69.
210. Arvandi M, Strasser B, Meisinger C, Volaklis K, Gothe RM, Siebert U, Ladwig KH, Grill E, Horsch A, Laxy M, Peters A, Thorand B. Gender differences in the association between grip strength and mortality in older adults: results from the KORA-age study. BMC Geriatrics 2016;16(1):201 [epub]
209. Adarkwah CC, Jegan N, Heinzel-Gutenbrunner M, Kühne F, Siebert U, Popert U, Donner-Banzhoff N, Kürwitz S. Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention – does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. BMC Med Inform Decis Mak. 2016;16(1):152. doi 10.1186/s12911-016-0393-1.
208. Hunger T, Schnell-Inderst P, Sahakyan N, Siebert U. Using expert opinion in health technology assessment: a guideline review. International Journal of Technology Assessment in Health Care 2016;32(3):131-9.
207. Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, Timmermann , Schnitzler A, Reese JP, Dodel R, EARLYSTIM-investigators. Cost-effectiveness of neurostimulation in Parkinson’s disease with early motor complications. Movement Disorders 2016;31(8):1183-91.
206. Bose-O’Reilly S, Schierl R, Nowak D, Siebert U, Jossep FW, Fradico TO, Yuyun I Ir. A preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia. Environmental Research 2016;149:274-81.
205. Luzak A; Schnell-Inderst P; Buhn S; Mayer-Zitarosa A; Siebert U. Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. European Journal of Public Health 2016; 26(3):498-505.
204. Jahn B, Rochau U, Kurzthaler C, Paulden M, Kluibenschädl M, Arvandi M, Kühne F, Goehler A, Krahn M, Siebert U. Lessons learned from a cross-model validation between a discrete event simulation model and a cohort state-transition model for personalized breast cancer treatment. Medical Decision Making 2016;36(3):375-90.
203. Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics 2016;34(3):227-44.
202. Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W, on behalf of the Austrian Myeloma Registry (AMR). Real-world use of 3rd line therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) analysis of the therapeutic landscape and clinical outcomes prior to the use of next generation myeloma therapeutics. PLoS One 2016;11(3): e0147381.
201. Leichtfried V, Basic D, Burtscher M, Gothe RM, Siebert U, Schobersberger W. Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation–independent of absolute altitude?. Sleep & Breathing 2016;20(1):435-42.
200. Volzke H, Caron P, Dahl L, de Castro JJ, Erlund I, Gaberscek S, Gunnarsdottir I, Hubalewska-Dydejczyk A, Ittermann T, Ivanova L, Karanfilski B, Khattak RM, Kusic Z, Laurberg P, Lazarus JH, Markou KB, Moreno-Reyes R, Nagy EV, Peeters RP, Pirags V, Podoba J, Rayman MP, Rochau U, Siebert U, Smyth PP, Thuesen BH, Troen A, Vila L, Vitti P, Zamrazil V, Zimmermann MB. for the Iodine Global Network (IGN) West Central Europe group. Ensuring effective prevention of iodine deficiency disorders. Thyroid 2016;26(2):189-96.
199. Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, Brixner DI. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. Oncologist 2016;21(2):196-204.
198. Latimer NR, Henshall C, Siebert U, Bell H. Treatment Switching: statistical and decision-making challenges and approaches. Int J Technol Assess Health Care 2016;32(3):160-6.
197. Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M., Kluibenschädl M., Krahn M., Siebert U. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. SpringerPlus 2015;4:752. doi: 10.1186/s40064-015-1440-6. eCollection 2015.
196. Christensen KD, Dukhovny D, Siebert U, Green RC. Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. [Review]. Journal of Personalized Medicine 2015;5(4):470-86.
195. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervary A, Brixner D, Siebert U. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. Journal of Comparative Effectiveness Research 2015;4(5):485-504.
194. Schnell-Inderst P, Mayer J, Lauterberg J, Hunger T, Arvandi M, Conrads-Frank A, Nachtnebel A, Wild C, Siebert U. Health technology assessment of medical devices: What is different? An overview of three European projects. Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):309-18.
193. Siebert U, Jahn B, Rochau U, Schnell-Inderst P, Kisser A, Hunger T, Sroczynski G, Mühlberger N, Willenbacher W, Schnaiter S, Endel G, Huber LA, Gastl G, on behalf of the Oncotyrol HTA & Outcomes Research Working Group. Oncotyrol – Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):330-40.
192. Mühlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U. The ONCOTYROL Prostate Cancer Outcome and Policy Model – Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening. Medical Decision Making 2015;35(6):758-72.
191. Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, Siebert U. The impact of generic substitution on health and economic Outcomes: A Systematic Review. Appl Health Econ Health Policy 2015;13 (Suppl 1):S21-33.
190. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma 2015; 56(8):2315-25.
189. Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leukemia Research and Treatment 2015:982395 [Epub 2015 Dec 10].
188. Oostvogels AJ, DE Wit GA, Jahn B, Cassini A, Colzani E, DE Waure C, Kretzschmar ME, Siebert U, Mühlberger N, Mangen MJ. Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review. Epidemiol Infect 2015;143(9):1791-802.
187. Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. Critical Reviews in Oncology-Hematology 2015;94(2):164-78.
186. Neumann A, Mostardt S, Biermann J, Gelbrich G, Goehler A, Geisler BP, Siebert U, Störk S, Ertl G, Angerrmann CE, Wasem J. Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clin Res Cardiol 2015;104(4):304-9.
185. Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A. Communicating the parameter uncertainty in the iqwig efficiency frontier to decision-makers. Health Econ 2015;24(4):481-90.
184. Diaby V, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):13-9.
183. Rogowski W, Payne K, Schnell-Inderst P, Manca A, Rochau U, Jahn B, Alagoz O, Leidl R, Siebert U. Concepts of ‘personalization’ in personalized medicine: implications for economic evaluation. Pharmacoeconomics 2015;33(1):49-59.
182. Geiger-Gritsch S, Oberaigner W, Mühlberger N, Siebert U, Ladurner M, Klocker H, Horninger W. Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck. Urologia Internationalis 2015; 94(4):419-27.
181. Steckling N, Bose-O’Reilly B, Pinheiro P, Plass D, Shoko D, Drasch G, Bernaudat L, Siebert U, Hornberg C. The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates. Environmental Health 2014;13:111. doi: 10.1186/1476-069X-13-111.
180. Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S on behalf of the BiomarCaRE consortium. BiomarCaRE – rationale and design of the European BiomarCaRE Project including 300,000 participants from 13 European countries. Eur J Epidemiol. 2014;29(10):777-90
179. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Saverno K, Brixner D, Radich J, Siebert U. Medical decision analysis for the first-line therapy of chronic myeloid leukemia. Leukemia & Lymphoma. 2014;55(8):1758-67.
178. Siebert U. Arvandi M. M Gothe R. Bornschein B. Eccleston D. L Walters D. Rankin J. De Bruyne B. F Fearon W. H Pijls N. Harper R. Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. Heart, Lung & Circulation 2014;23(6):527-33.
177. Blatt, CR, Storb, B, Mühlberger, N, Farias, MR, Siebert, U. Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment. Brazilian Journal of Pharmaceutical Sciences 2014; 50(2):345-352.
176. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014;58(8):1064-71.
175. Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Systematic assessment of decision-analytic models for chronic myeloid leukemia. [Review]. Appl Health Econ Health Policy 2014;12(2):103-15.
174. Rautenberg T. Siebert U. Arnold D. Bennouna J. Kubicka S. Walzer S. Ngoh C. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.[Erratum appears in J Med Econ. 2014 Mar;17(3):231]. Journal of Medical Economics 2014;17(2):99-110.
173. Hunger T, Schnell-Inderst P, Hintringer K, Schwarzer R, Seifert-Klauss V, Gothe H, Wasem J, Siebert U. Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. Int J Public Health 2014;59(1):175-87.
172. Saverno K, Gothe H, Schuessel K, Biskupiak J, Schulz M, Siebert U, Brixner D. Consideration of international generic distribution policies on patient outcomes in the United States and Germany. Pharmazie 2014, 69(3):238-40.
171. Stollenwerk B, Gandjour A, Lüngen M, Siebert U. Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. Eur J Health Econ 2013;14(6): 1035-48.
170. Mangen MJ, Plass D, Havelaar AH, Gibbons CL, Cassini A, Mühlberger N, van Lier A, Haagsma JA, Brooke RJ, Lai T, de Waure C, Kramarz P, Kretzschmar ME; BCoDE consortium. The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseases. PLoS One. 2013 Nov 20;8(11):e79740. doi: 10.1371/journal.pone.0079740. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/caf33818-3453-4e30-b307-7526427b09b7.
169. Siebert U, Rochau U, Claxton K. When is enough evidence enough? – Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen – German Journal for Quality in Health Care 2013;107(7):575-84.
168. Weinberger B. Schirmer M. Matteucci Gothe R. Siebert U. Fuchs D. Grubeck-Loebenstein B. Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons. PLoS One 2013;8(12):e82967. doi: 10.1371/journal.pone.0082967. eCollection 2013.
167. Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM, and the International Task Force on Decision Criteria. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. International Journal of Technology Assessment in Health Care 2013 29(4): 456-65.
166. Sroczynski G. Siebert U. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology 2013;10(10):572-4.
165. Institute for Quality and Efficiency in Health Care (IQWIG). Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments. Executive Summary. IQWiG Reports – Commission No. G09-01, IQWiG-Report – Nr. 190. Cologne, Germany: Institute for Quality and Efficiency in Health Care, 2013;1-626.
164. Caro JJ. Eddy DM. Hollingworth W. Tsevat J. McDonald KM. Wong JB. Briggs AH. Siebert U. Kuntz KM. ISPOR-SMDM task force’s recommendations for good modeling practices-reply to letter to the editor by Corro Ramos.Value Health. 2013;16(6):1108.
163. Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, Dodel R, Reese JP. Cost-effectiveness of deep brain stimulation in patients with Parkinson’s disease. Mov Disord 2013;28(6):763-71.
162. Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; on behalf of the members of the Swiss IBD Cohort Study Group. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gastroenterol Hepatol 2013;25(7):790-797.
161. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16(2):231-250.
160. Dams J, Klotsche J, Bornschein B, Reese JP, Balzer-Geldsetzer M, Winter Y, Schrag A, Siderowf A, Oertel WH, Deuschl G, Siebert U, Dodel R. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson’s disease. Health Qual Life Outcomes 2013;11(1):35
159. Strasser B, Siebert U, Schobersberger W. Effects of resistance training on respiratory function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Sleep Breath 2013;17(1):217-26.
158. Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka S, von Känel R, Begré S, Sulz M, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. Predictors of Temporary and Permanent Work Disability in Patients with Inflammatory Bowel Disease Results of the Swiss Inflammatory Bowel Disease Cohort Study. Inflammatory Bowel Diseases 2013;19(4):847-55.
157. Froeschl B, Bornschein B, Brunner-Ziegler S, Conrads-Frank A, Eisenmann A, Gartlehner G, Grillich L, Kaminski A, Muehlberger N, Pertl D, Schnell-Inderst P, Sroczynski G, Siebert U, Thaler K, Wild C, Wurm J, Zechmeister I, Zsifkovits J, Horvath K, Pueringer U, Grouven U, Kurth T, Luehmann D, Swart E, Neumann A, Landauer R. Methodenhandbuch für Health Technology Assessment Version 1.2012. Eine Kooperation von Donau-Universität Krems (DUK), EBM Review Center Graz, Gesundheit Österreich GmbH (GÖG), Ludwig Boltzmann Institut für HTA (LBI-HTA) und Privater Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik (UMIT). Wien, Österreich: Im Auftrag des Bundesministeriums für Gesundheit, 2012;1-425.
156. Kretzschmar M, Mangen MJ, Pinheiro P, Jahn B, Fevre EM, Longhi S, Lai T, Havelaar AH, Stein C, Cassini A, Kramarz P, BCoDE consortium. New methodology for estimating the burden of infectious diseases in Europe. PLoS Med 2012;9(4):e1001205. doi: 10.1371/journal.pmed.1001205
155. Siebert U, Rochau U. Personalisierte Krebstherapie. PharmacoEconomics 2012;10:87-104
154. Blatt C, Bernado NL, Rosa JA, Bagatini F, Alexandre RF, Balbinotto NG, Siebert U, Farias M. An estimate of the cost of Hepatitis C treatment for the Brazilian Health System. Value in Health Regional Issues 2012;1(2):129–35.
153. Faulkner E, Annemans L, Garrison L, Helfand M, Holtdorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 2012;15(8):1162-71.
152. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P. Predicted Effects of Treatment for HCV Infection Vary Among European Countries. Gastroenterology 2012;143:974-85.e14.
151. Dimai HP, Redlich K, Schneider H, Siebert U, Vierstein H, Mahlich J. [Direct and indirect costs of fractures due to osteoporosis in Austria]. [German]. Gesundheitswesen 2012 74(10):e90-8.
150. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making 2012;32(5):690-700.
149. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health 2012;15(6)812-20.
148. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32(5):667-77.
147. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health 2012;15(6):796-803.
146. Luce BR, Drummond MF, Dubois RW, Neumann PJ, Joensson B, Siebert U, Schwartz JS. Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research 2012;1(5):431-40
145. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 2012;13(12):1405-17.
144. Saverno KR, Rochau U, Stenehjem DD, Morley K, Siebert U, Brixner DI. Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients. J Manag Care Pharm 2012;18(6):457-63.
143. Strasser B, Arvandi M, Siebert U. Resistance training, visceral obesity and inflammatory response: a review of the evidence. Obes Rev 2012;13(7):578-91
142. Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J.Economic burden of osteoporotic fractures in Austria. Health Econ Rev 2012;27;2(1):12. doi: 10.1186/2191-1991-2-12.
141. Drummond M, Neumann P, Jönsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Can we reliably benchmark health technology assessment organizations? International Journal of Technology Assessment in Health Care 2012;28(2):159-65.
140. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group – Part 5. ISPOR 2011. Internet: http://www.ispor.org/taskforces/GRPModelingTf.asp
139. Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss V, Gothe H, Wasem J, Siebert U. Individuelle Gesundheitsleistungen. Schriftenreihe des Deutschen Instituts für Medizinische Dokumentation und Information im Auftrag des Deutschen Bundesministeriums für Gesundheit. Health Technology Assessment. Vol. 113 (1. Auflage). Köln: DAHTA@DIMDI, 2011.
138. Ammenwerth E, Schnell-Inderst P, Hörbst A. Patient Empowerment by Electronic Health Records: First Results of a Systematic Review on the Benefit of Patient Portals. e-health Across Borders without Boundaries. EFMI Special Topic Conference (STC), April 14-15. Laško, Slovenia, Studies in Health Technology and Informatics. Amsterdam: IOS Press 2011; 165:63-67.
137. Siebert U. [Transparent Decisions in Public Health Using Systematic Decision Analysis]. [German]. In: Schwartz FW, Badura B, Busse R, Leidl R, Raspe H, Siegrist J, Walter U (eds.): [The Public Health Book. Health and Health Care]. 3nd ed. Urban & Fischer: Munich, 2011.
136. Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, Frauscher F, Schennach H, Bartsch G. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012;57(1):57-62.
135. Krobot KJ, Wagner A, Siebert U. Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins. Eur J Cardiovasc Prev Rehabil 2012;19(1):109-17
134. Baeuml J, Bose-O’Reilly S, Lettmeier B, Maydl A, Messerer K, Roider G, Drasch G, Siebert U. Applicability of two mobile analysers for mercury in urine in small-scale gold mining areas. International Journal Hygiene Environmental Health 2011;215(1):64-7.
135. Sels J, Tonino P, Siebert U, Fearon W, Van’t Veer M, De Bruyne B, Pijls N. Fractional Flow Reserve in Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Experience From the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) Study. J Am Coll Cardiol Intv 2011;4(11):1183-9.
133. Nuijten MJ, Aultman R, Carpeno Jde C, Vergnenegre A, Chouaid C, Walzer S, Siebert U. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research & Opinion 2011; 27(11):2193-201.
132. Baeuml J, Bose-O’Reilly S, Gothe RM, Lettmeier B, Roider G, Drasch G, Siebert U. Human biomonitoring data from mercury exposed miners in six artisanal small-scale gold mining areas in Asia and Africa. Minerals 2011;1(1):122-143.
131. Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel W, Siebert U, Dodel R. Modelling the cost effectiveness of treatments for Parkinson´s Disease – A methodological review. Pharmacoeconomics 2011;29(12):1025-49.
130. Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss VR, Gothe H, Wasem J, Siebert U. Individual health services. GMS Health Technol Assess. 2011;7:Doc05
129. Oberaigner W, Daniaux M, Geiger-Gritsch S, Knapp R, Siebert U, Buchberger W. Introduction of organised mammography screening in Tyrol: results following first year of complete rollout. BMC Public Health 2011;11:91. doi: 10.1186/1471-2458-11-91
128. Leitner H, Bose-O’Reilly S, Oberaigner W, Mark M, Brezinka C, Siebert U. [Perinatal Mortality by Mother’s Country of Origin in Tyrol 2000-2008]. [German]. Gesundheitswesen 2011;73(8-9):469-76.
127. Oberaigner W, Siebert U. Do women with cancer have better survival as compared to men after adjusting for staging distribution? Eur J Public Health 2011;21(3)291:387-391.
126. Jahn R, Diehm C, Driller E, Hessel F, Ommen O, Pfaff H, Siebert U, Pittrow D, Wasem J, Neumann A. Effect of guideline-orientation on the outcomes of peripheral arterial disease in primary care. Current Medical Research and Opinion 2011;27(6):1183-1190.
125. Goehler A, Geisler BP, Manne JM, Jahn B, Conrads-Frank A, Schnell-Inderst P, Gazelle GS, Siebert U. Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review. Pharmacoeconomics 2011;29(9):753-69.
124. Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Kramer A, Siebert U. Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis. Eur J Cancer 2011;47(11):1633-1646.
123. von Campenhausen S, Winter Y, Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Botzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP. Costs of illness and care in Parkinson’s Disease: An evaluation in six countries. Eur Neuropsychopharmacol 2011;21(2):180-91.
122. Jahn R, Diehm C, Driller E, Hessel F, Ommen O, Pfaff H, Siebert U, Pittrow D, Wasem J, Neumann A. Effect of guideline-orientation on the outcomes of peripheral arterial disease in primary care. Current Medical Research and Opinion 2011;27(6)286:1183-1190.
121. Steckling N, Boese-O’Reilly S, Gradel C, Gutschmidt K, Shinee E, Altangerel E, Badrakh B, Bonduush I, Surenjav U, Ferstl P, Roider G, Sakamoto M, Sepai O, Drasch G, Lettmeier B, Morton J, Jones K, Siebert U, Hornberg C. Mercury exposure in female artisanal small-scale gold miners (ASGM) in Mongolia: An analysis of human biomonitoring (HBM) data from 2008. Sci Total Environ 2011;409(5):994-1000.
120. Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto J P, Porta C, Walzer S, Siebert, U. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. ClinicoEconomics and Outcomes Research 2011;3:19-27.
119. Oberaigner W, Buchberger W, Frede T, Daniaux M, Knapp R, Marth C, Siebert U. Introduction of organised mammography screening in Tyrol: results of a one-year pilot phase. BMC Public Health 2011;11(91):1-28.
118. Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation 2010;122(24):2545-50.
118. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010;19(10):1117-27.
117. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. IQWiG methods – a response to two critiques. Health Econ 2010;19(10):1137-8.
116. Siebert U, Schnell-Inderst P, Hintringer K. Health Technology Assessment. medicine & health 2011. GoingInternational Polak, G., 2010;229-31.
115. Oberbichler S, Memelink M, Wozak F, Jahn B, Schabetsberger T, Hoerbst A, Siebert U. INSYDE – Integration of Health System Data and Exchange – A Status Report, OCG Books 2010;264:181-87.
114. Neumann PJ, Drummond MF, Jonsson B, Luce BR, Schwartz JS, Siebert U, Sullivan SD. Evaluating HTA principles – Letters to the Editor. Int J Technol Assess Health Care 2010;26(4):429-30.
113. Nuijten M, Heigener D, Bischoff H, Chouaid C, Vergnenègre A, Carpeño J, Aultman R, Walzer S, Siebert U. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010;69(Supplement 1):4-10.
112. Luce BR, Drummond M, Jonsson B, Neumann PJ, Schwartz JS, Siebert U, Sullivan SD. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010;88(2):256-76.
111. Schmidt T, Mühlberger N, Chemelli-Steingruber IE, Strasak A, Kofler B, Chemelli A, Siebert U. Benefit, risks and cost-effectiveness of screening for abdominal aortic aneurysm. Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2010;182(7):573-80.
110. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van’t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 2010;56(3):177-84.
109. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 2010;11(7):989-1002.
108. Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med 2010;40(5):397-415.
107. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U. [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]. Health Technology Assessment. Cologne: DIMDI, 2010;1-127.
106. Basner M, Siebert U. Markov processes for the prediction of aircraft noise effects on sleep. Medical Decision Making 2010; 30(2):275-89.
105. Jahn B, Theurl E, Siebert U, Pfeiffer KP. Tutorial in medical decision modeling incorporating waiting lines and queues using discrete event simulation. Value Health 2010;13(4):501-6.
104. Grander W, Dunser M, Stollenwerk B, Siebert U, Dengg C, Koller B, Eller P, Tilg H. C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest 2010;138(4):856-62.
103. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U. [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]. GMS Health Technol Assess 2010;6(Doc05 ):1-13.
102. Ammenwerth E, Schnell-Inderst P, Siebert U. Vision and challenges of Evidence-Based Health Informatics: a case study of a CPOE meta-analysis. Int J Med Inform 2010;79(4):e83-8.
101. Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R. Uncertainty assessment of input parameters for economic evaluation: Gauss’s error propagation, an alternative to established methods. Med Decis Making 2010;30(3):304-13.
100. Oberaigner W, Buchberger W, Frede T, Knapp R, Marth C, Siebert U. Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. BMC Public Health 2010;10(1):86.
99. Konig A, Bleie O, Rieber J, Jung P, Schiele TM, Sohn HY, Leibig M, Siebert U, Klauss V. Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. Clin Res Cardiol 2010;99(2):83-91.
98. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem Z, Siebert U. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hep 2010;17(1):34-50.
97. Bose-O’Reilly S, Drasch G, Beinhoff C, Rodrigues-Filho S, Roider G, Lettmeier B, Maydl A, Maydl S, Siebert U. Health assessment of artisanal gold miners in Indonesia. Sci Total Environ 2010;408(4):713-25.
96. Bose-O’Reilly S, Drasch G, Beinhoff C, Tesha A, Drasch K, Roider G, Taylor H, Appleton D, Siebert U. Health assessment of artisanal gold miners in Tanzania. Sci Total Environ 2010;408(4):796-805.
95. International Working Group for HTA Advancement, Neumann PJ, Drummond MF, Jönsson B, Luce BR, Schwartz JS, Siebert U, Sullivan SD. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? International Journal of Technology Assessment in Health Care 2010; 26(1):71-78.
94. Schnell-Inderst P, Schwarzer R, Gohler A, Grandi N, Grabein K, Stollenwerk B, Manne J, Klauss V, Siebert U, Wasem J. Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care 2010;26(1):30-9.
93. Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010;25(15):2604-12.
92. Tonino PA, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van’t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. New England Journal of Medicine 2009;360(3):213-24.
91. Trikalinos TA, Siebert U, Lau J. Decision-analytic modelling to evaluate benefits and harms of medical tests. Medical Tests-White Paper Series. Rockville: Agency for Healthcare Research and Quality (AHRQ), 2009;1-15.
90. von Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Botzel K, Siebert U, Oertel WH, Dodel R, Poewe W. [Cost of illness and health service patterns in Morbus Parkinson in Austria]. Wien Klin Wochenschr 2009;121(17-18):574-82.
89. Schwarzer R, Schnell-Inderst P, Grabein K, Gohler A, Stollenwerk B, Grandi N, Klauss V, Wasem J, Siebert U. [Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]. Z Evid Fortbild Qual Gesundhwes 2009;103(6):319-29.
88. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part III. Value in Health 2009; 12(8):1062-1073.
87. Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta Oncol 2009;48(7):984 – 991.
86. Konig A, Bleie O, Rieber J, Jung P, Schiele TM, Sohn HY, Leibig M, Siebert U, Klauss V. Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. Clin Res Cardiol 2010;99(2):83-91.
85. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009;12(8):1053-1061.
84. Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to evaluate benefits and harms of medical tests: Uses and limitations. Med Decis Making 2009;29(5):E22-9.
83. Mehrhof F, Loffler M, Gelbrich G, Ozcelik C, Posch M, Hense HW, Keil U, Scheffold T, Schunkert H, Angermann C, Ertl G, Jahns R, Pieske B, Wachter R, Edelmann F, Wollert KC, Maisch B, Pankuweit S, Erbel R, Neumann T, Herzog W, Katus H, Muller-Tasch T, Zugck C, Dungen HD, Regitz-Zagrosek V, Lehmkuhl E, Stork S, Siebert U, Wasem J, Neumann A, Gohler A, Anker SD, Kohler F, Mockel M, Osterziel KJ, Dietz R, Rauchhaus M. A network against failing hearts–introducing the German “Competence Network Heart Failure”. Int J Cardiol 2010;145(1):135-8.
82. Konig A, Bleie O, Dudek D, Marso S, Rogers JH, Dave R, Tanaka K, Siebert U, Wijns W, Klauss V. Coronary plaque dimensions and composition by intravascular ultrasound radio frequency lesion segment analysis in stable and unstable angina patients. Coron Artery Dis 2009;20(5):309-16.
81. Schwarzer R, Siebert U. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. Int J Technol Assess Health Care 2009;25(3):305-14.
80. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009;27(37):5133-41.
79. Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB, German Hepatitis C Model (GEHMO) Group, International Hepatitis Interventional Therapy (IHIT) Group. Clinical effectiveness and cost-effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: A decision analysis on new German guidelines. Pharmacoeconomics 2009;27(4):341-54.
78. Neumann A, Jahn R, Diehm C, Driller E, Hessel F, Lux G, Ommen O, Pfaff H, Siebert U, Wasem J, and on behalf of the Patient Care Evaluation-Peripheral Arterial Disease (PACE-PAD) Study Investigators. Presentation and medical management of peripheral arterial disease in general practice: rationale, aims, design and baseline results of the PACE-PAD Study. J Public Health 2009;17(2):127-35.
77. Göhler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility Estimates for Decision – Analytic Modeling in chronic heart failure – health states based on New York Heart Association classes and number of rehospitalizations. Value in Health 2009;12(1):185-7.
76. Geisler BP, Siebert U, Gazelle GS, Cohen DJ, Göhler A. Deterministic sensitivity analysis for First-Order Monte Carlo Simulations: A technical note. Value in Health 2009;12(1):96-7.
75. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9(1):34.
74. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, Zeuzem S, Siebert U. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009;19(3):245-53.
73. Stollenwerk B, Gerber A, Lauterbach KW, Siebert U. The German Coronary Artery Disease Risk Screening Model: Development, validation and application of a decision-analytic model for coronary artery disease prevention with statins. Med Decis Making 2009;29:619-33.
72. Siebert U, Conrads-Frank A, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Mühlberger N. DALYs in chronic hepatitis C – a pan-European perspective In: Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer, 2009;1323-1334.
71. Siebert U. Die Bewertung der Kosteneffektivität von Impfungen unter Berücksichtigung von Public Health Aspekten. Public Health Forum 2009;17(2):9.e1-9.e3.
70. Göhler A, Conrads-Frank A, Worrell SS, Geisler BP, Halpern EF, Dietz R, Anker SD, Gazelle GS, Siebert U. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. Eur J Heart Fail 2008;10(10):1026-32
69. Boese-O’Reilly S, Drasch G, Lettmeier B, Roider G, Siebert U. Reply to the letter to the editor by J.G. Dorea “Health hazard for infants: Breast-milk mercury or non-breastfeeding? A dilemma for mothers exposed to mercury vapours”. Int J Hyg Environ Health 2008;212(2):235-7.
68. Institute for Quality and Efficiency in Health Care (IQWiG). Methods for assessment of the relation of benefits to costs in the German Statutory Health Care System. V. 1.0. (Members of the IQWiG International Expert Panel: Attella V, Caro J, Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U). Cologne: IQWiG, 2008;68.
67. Siebert U, Bornschein B, Schnell-Inderst P, Rieber J, Pijls N, Wasem J, Klauss V. [Measurement of fractional flow reserve to guide the decision on percutaneous coronary interventions] [German]. Health Technology Assessment Vol. 69 (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health). Cologne, Germany: DIMDI, 2008;1-173.
66. Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U. Progression-free survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care 2008;24(4):371-83.
65. Lettmeier B; Mühlberger N, Schwarzer E, Sroczynski G, Wright D, Zeuzem S, Siebert U. Market Uptake of New Antiviral Drugs for the Treatment of Hepatitis C. Journal of Hepatology 2008;49(4):528-36.
64. Böse-O’Reilly S, Lettmeier B, Roider G, Siebert U, Drasch G. Mercury in breast milk – A health hazard for infants in gold mining areas? Int J Hyg Environ Health 2008:211(5-6):615-23.
63. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic Review. J Am Med Inform Assoc. 2008;15(5):585-600
62. Drummond M, Schwartz JS, Jönsson B, Luce B, Neumann P, Siebert U, Sullivan S. Response from the authors of “Key principles for the improved conduct of health technology assessments for resource allocation decisions”. [Letter] Int J Technol Assess Health Care 2008;24(3):367-8.
61. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;24(3):244-58; discussion 362-8.
60. Bose-O’Reilly S, Lettmeier B, Gothe RM, Beinhoff C, Siebert U, Drasch G. Mercury as a serious health hazard for children in gold mining areas. Environmental Research 2008; 107(1):89-97.
59. Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. International Journal of Technology Assessment in Health Care 2008;24(2):184-92
58. König A, Kilian E, Sohn HY, Rieber J, Schiele TM, Siebert U, Gothe RM, Reichart B, Klauss V. Assessment and characterization of time-related differences in plaque composition by intravascular ultrasound-derived radiofrequency analysis in heart transplant recipients. Journal of Heart & Lung Transplantation 2008;27(3):302-9.
57. Böse-O´Reilly S, Wermuth I, Hellmann J, Siebert U, Lob-Corzilius T. [Promotion of breast feeding in paediatric outpatient settings]. [German] Gesundheitswesen 2008;70(Suppl 1):S34-36.
56. Janne d’Othée B, Siebert U, Cury R, Jadvar H, Dunn EJ, Hoffmann U. A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol 2008;65(3):449-61.
55. Stempfle HU, Alt A, Stief J, Siebert U. The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies. Journal of Heart & Lung Transplantation 2008;27(2):222-8.
54. Dodel R, Peter H, Spottke A, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G. Health-Related Quality of Life in Patients with Narcolepsy. Sleep Medicine 2007:8(7-8):733-41.
53. Meissner OA, Schmedt CG, Hunger K, Hetterich H, Sroka R, Rieber J, Babaryka G, Steckmeier BM, Reiser M, Siebert U, Mueller-Lisse U. Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy. Eur Radiol 2007;17(9):2384-93.
52. Schneider A, Schwarz TF, Hammerschmidt T, Rash RM, Siebert U. [Treatment patterns and costs of unclear and abnormal cervical conditions in Germany]. [German] Geburtshilfe und Frauenheilkunde 2007;67(8):859-865.
51. Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U. [Long-term public health impact of vaccination against cervical cancer in Germany]. [German] Geburtshilfe und Frauenheilkunde 2007;67(8):850-858.
50. Schneider A, Schwarz TF, Hammerschmidt T, Siebert U. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany]. [German] Medizinische Klinik 2007; 102(7):515-23.
49. Fearon WF, Tonino PA, De Bruyne B, Siebert U, Pijls NHJ, for the FAME Study Investigators. Rationale and Design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) Study. American Heart Journal 2007;154(4):632-6
48. König A, Leibig M, Rieber J, Schiele TM, Theisen K, Siebert U, Gothe RM, Klauss V. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. American Heart Journal 2007;153(6):979.e1-8.
47. Müller T, Koppikar S, Taylor RM, Carragher F, Schlenck B, Heinz-Erian P, Kronenberg F, Ferenci P, Tanner S, Siebert U, Staudinger R, Mieli-Vergani G, Dhawan A. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson’s disease in children. J Hepatol 2007; 47(2):270-6.
46. Dodel R, Peter H, Spottke A, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G. Health-Related Quality of Life in Patients with Narcolepsy. Sleep Medicine 2007 [in press]
45. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP Titel: Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 2007; 22(7):938-45.
44. Meissner OA, Schmedt CG, Hunger K, Hetterich H, Sroka R, Rieber J, Babaryka G, Steckmeier BM, Reiser M, Siebert U, Mueller-Lisse U. Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy. Eur Radiol. 2007; 17(9):2384-93.
43. Basner M, Siebert U. Markov processes for prediction of aircraft-noise effects on sleep [Original title: Markov-Prozesse zur Vorhersage fluglaermbedingter Schlafstoerungen]. Somnologie 2006;10:176-191.
42. Siebert U. Cost-Effectiveness. In: King and Yeung (eds.). Interventional Cardiology. McGraw-Hill, New York: 2007, 767-82.
41. Siebert U. [Decision Analysis]: In: Schlipköter U, Wildner M (eds.): [Manual of Infectious Diseases Epidemiology] Hans Huber, Bern: 2006; 87-95.
40. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K. The costeffectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006;10(32):1-112.
39. Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, Siebert U. A Systematic Meta-Analysis of the Efficacy and Heterogeneity of Disease Management Programs in Congestive HeartFailure. J Cardiac Failure 2006, 12 (7): 554-67
38. Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of Using N-terminal pro-Brain Natriuretic Peptide to Guide the Diagnostic Assessment and Management of Dyspneic Patients in the Emergency Department. American Journal of Cardiology, 2006, 98 (6): 800-5
37. Zietemann V, Zietemann P, Weitkunat R, Kwetkat A. Depressionshäufigkeit in Abhängigkeit von verschiedenen Erkrankungen bei geriatrischen Patienten. Der Nervenarzt 2006
36. Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006;23(4):393-406.
35. Basner M, Siebert U. Markov processes for prediction of aircraft-noise effects on sleep [Original title: Markov-Prozesse zur Vorhersage fluglaermbedingter Schlafstoerungen]. Somnologie 2006;10:176-191.
34. Siebert U. Entscheidungsanalysen in HTA. Ziele, Stärken, Limitationen. HTA-Newsletter ITA/Österreichische Akademie der Wissenschaften 2006 (45): 1-2. http://epub.oeaw.ac.at/ita/htanewsletter/ htaNL0306.pdf
33. Rohde V, Grabein K, Hessel F, Siebert U, Wasem J. Orchiektomie versus medikamentöse Therapie mit LH-RH-Analoga zur Behandlung des fortgeschrittenen Prostatakarzinoms. Health Technology Assessment Vol. 140. Serie des Deutschen Instituts für Medizinische Dokumentation und Information, im Auftrag des Bundesministeriums für Gesundheit. Köln: DIMDI, 2006
32. Sroczynski G, Rafetseder O. Jonas S., Siebert U. Antivirale Kombinationstherapie bei Patienten mit chronischer Hepatitis C in Österreich. Gesundheitsökonomische Evaluation der Kombinationstherapie mit Interferon/Peginterferon und Ribavirin. ITA-Projektbericht Nr. b29 . (48 pages. Vienna: Institut für Technologiefolgenabschätzung, Österreichische Akademie der Wissenschaften, 2006.
31. Hoffmann U, Pena AJ, Cury RC, Abbara S, Ferencik M, Moselewski F, Siebert U, Brady TJ, Nagurney JT. Cardiac CT in emergency department patients with acute chest pain. Radiographics 2006;26(4):963-978; discussion 979-80.
30. Cury RC, Cattani CA, Gabure LA, Racy DJ, de Gois JM, Siebert U, Lima SS, Brady TJ. Diagnostic Performance of Stress Perfusion and Delayed-Enhancement MR Imaging in Patients with Coronary Artery Disease. Radiology 2006;240(1):39-45.
29. Rieber J. Huber A, Erhard I, Mueller S, Schweyer M, Koenig A, Schiele TM, Theisen K, Siebert U, Schoenberg SO, Reiser M, Klauss V. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: A comparison with coronary angiography and fractional flow reserve. European Heart Journal 2006;27(12):1456-71.
28. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Hölzel D, Goldie SJ. The German Cervical Cancer Screening Model: Development and validation of a decisionanalytic model for cervical cancer screening in Germany. Eur J Pub Health 2006;16(2):185-92.
27. Hoffmann U. Siebert U. Bull-Stewart A. Achenbach S. Ferencik M. Moselewski F. Brady TJ. Massaro JM. O’Donnell CJ. Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort–consequences for progression studies. Eur J Radiol 2006;57(3):396-402.
26. Meissner OA. Rieber J. Babaryka G. Oswald M. Reim S. Siebert U. Redel T. Reiser M. Mueller-Lisse U. Intravascular optical coherence tomography: comparison with histopathology in atherosclerotic peripheral artery specimens. J Vasc Interv Radiol 2006;17(2):343-9.
25. Meissner OA. Rieber J. Babaryka G. Oswald M. Reim S. Siebert U. Redel T. Eibel R. Mueller-Lisse U. Reiser M. Mueller-Lisse UG. [Intravascular optical coherence tomography: differentiation of atherosclerotic plaques and quantification of vessel dimensions in crural arterial specimens]. [German] Rofo 2006;178(2):214-20.
24. Wasem J. Sroczynski G. Aidelsburger P. Buchberger B. Hessel F. Conrads-Frank A. Peters-Blöchinger A. Kurth BM. Wong JB. Rossol S. Siebert U. [Health economics of chronic infectious diseases: the example of hepatitis C]. [German] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2006;49(1):57-63.
23. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 2006;37(1):193-8.
22. Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL Jr. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J 2006;151(1):48-54.
21. Baierl V, Baumgartner S, Pollinger B, Leibig M, Rieber J, Konig A, Krotz F, Sohn HY, Siebert U, Haimerl W, Duhmke E, Theisen K, Klauss V, Schiele TM. Three-year clinical follow-up after strontium-90/yttrium-90 Beta-irradiation for the treatment of in-stent coronary restenosis. Am J Cardiol 2005;96(10):1399-403.
20. Brandstaedter D, Spieker S, Ulm G, Siebert U, Eichhorn TE, Krieg JC, Eggert K, Oertel WH. Development and evaluation of the Parkinson Psychosis Questionnaire: A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson?s disease. J Neurol, 2005; 252(9):1060-6
19. Erhard I, Rieber J, Jung P, Hacker M, Schiele T, Stempfle HU, König A, Baylacher M, Theisen K, Siebert U, Klauss V. The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stress echocardiography. Zeitschrift fur Kardiologie 2005;94(5):321-7.
18. Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U, and the European Haemophilia Economic Study Group. Cost effectiveness of haemophilia treatment: A Cross-National Assessment. Blood Coagul Fibrinolysis 2005;16(7):477-85.
17. Rieber J, Gockel K, Koschyk D, Erhard I, Koenig A, Schiele TM, Theisen K, Siebert U, Klauss V. Application, feasibility, and efficacy of a combined intravascular ultrasound and stent delivery system: results from a prospective multicenter trial. J Interv Cardiol 2005;18(5):367-74.
16. Von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Olesen J, Oertel W, Siebert U, Berger K, Dodel R. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005;15(4):473-90
15. Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 2005; 23(8):817-36.
14. Stempfle HU, König A, Drescher E, Siebert U, Klauss V. Discrepancy between morphologic and functional criteria of optimal stent deployment using intravascular ultrasound and pressure derived myocardial fractional flow reserve. Int J Cardiovasc Intervent 2005;7(2):101-7.
13. Schiele TM, König A, Rieber J, Erhard I, Leibig M, Theisen K, Siebert U, Klauss V. Sirolimus-eluting stent implantation and beta-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. Am Heart J 2005;150(2):351-7.
12. Erhard I, Rieber J, Jung P, Hacker M, Schiele T, Stempfle HU, Konig A, Baylacher M, Theisen K, Siebert U, Klauss V Institution. The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stressechocardiography. Zeitschrift für Kardiologie 2005;94(5):321-7.
11. Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, Graf von der Schulenburg JM, Wong JB, Rossol S. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ 2005;2(6);112-23
10. Gazelle GS, McMahon PM, Siebert U, Beinfeld MT. Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 2005;235(2):361-370
9. Lindgren P, von Campenhausen S, Spottke EA, Siebert U, Dodel R. Cost of Parkinson?s disease in Europe. European Journal of Neurology 2005;12 (Suppl. 1): 68-73
8. Meissner OA, Rieger J, Weber C, Siebert U, Steckmeier B, Reiser M, Schoenberg SO. Critical limb ischemia: hybrid-MR angiography compared with digital subtraction angiography. Radiology 2005;235(1):308-18.
7. Rieber J, Jung P, Erhard I, Koenig A, Hacker M, Schiele TM, Segmiller T, Stempfle HU, Theisen K, Siebert U, Klauss V. Comparison of pressure measurement, dobutamine contrast stress echocardiography and SPECT for the evaluation of intermediate coronary stenoses. The COMPRESS trial. Int J Cardiovasc Intervent 2004;6(3-4):142-47
6. Grill E, Hessel F, Siebert U, Schnell-Inderst P, Kunze S, Nickisch A, Wasem J. Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis. BMC Public Health 2005;5(1):12
5. Klauss V, Erdin P, Rieber J, Leibig M, Stempfle HU, König A, Baylacher M, Theisen K, Haufe MC, Sroczynski G, Schiele T, Siebert U. Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis. Heart (British Cardiac Society) 2005;91(2):203-206.
4. Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB [Letter]. Antiviral treatment initiation costs in chronic hepatitis C. Gut 2005;54(1):172-3.
3. Siebert U, Sroczynski G, German Hepatitis C Model (GEHMO) Group, HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Tech Assess Health Care 2005;21(1):55-65.
2. Hessel F, Grabein K, Schnell-Inderst P, Siebert U, Caspary W, Wasem J. Extracorporal artificial liver support systems in patients with acute liver failure or acute ecompensation of chronic liver disease. Extracorporal artificial liver support systems in patients with acute liver failure or acute-on-chronic liver failure. [German; original title: Extrakorporale artifizielle Leberunterstützungssysteme bei akutem Leberversagen oder einer akuten Dekompensation eines chronischen Leberleidens]. Health Technology Assessment. (Series of the German Institute for Medical Documentation and Information
1. Siebert U. Using Decision-Analytic Modelling to Transfer International Evidence from Health Technology Assessment to the Context of the German Health Care System. A HTA Methods Report [German; original title: Entscheidungsanalytische Modelle zur Sicherung der Übertragbarkeit internationaler Evidenz aus HTA auf den Kontext des deutschen Gesundheitssystems. Ein HTA Methodenreport] Health Technology Assessment Vol 15. (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security). 90 pages. Köln: DIMDI, 2005.